@article{article, title  = {{A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy.}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2020}},

 month = {{2}},

 author = {{Steinberg GD and Palou-Redorta J and Gschwend JE and Tran B and Loriot Y and Daneshmand S and Roupret M and Santiago-Walker AE and Switzky JC and Major C and Baig M et al}},

 doi = {{10.1200/jco.2020.38.6_suppl.tps603}},

 volume = {{38}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{6_suppl}},

 pages = {{TPS603-TPS603}},

 note = {{Accessed on 2025/01/13}}}